NC410

DRUG3 trials

Sponsors

NextCure, Inc., Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

Advanced or Metastatic Solid TumorsCervical CancerColo-rectal CancerEndometrial CancerEsophageal CancerGastric CancerHead Neck CancerLung Cancer

Phase 1

A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

TerminatedNCT04408599

NextCure, Inc.Advanced or Metastatic Solid Tumors, Colo-rectal Cancer, Gastric Cancer +1

Start: 2020-06-10End: 2023-07-06Updated: 2024-07-25

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

TerminatedNCT05572684

NextCure, Inc.Advanced or Metastatic Solid Tumors, Cervical Cancer, Colo-rectal Cancer +9

Start: 2022-10-06End: 2025-04-30Updated: 2026-08-13

Phase 2

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

RecruitingNCT06941857

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPancreatic Cancer

Start: 2025-09-04End: 2028-12-01Target: 20Updated: 2026-05-05

Related Papers

Phase II study of NC410 and FOLFIRINOX in combination with nivolumab with or without ipilimumab in patients with treatment-naive metastatic pancreatic cancer.

Journal of Clinical Oncology2026-05-28

A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.

Journal of Clinical Oncology2024-06-012 citations

487 NC410, a fusion protein of LAIR-2 (Leukocyte Associated Immunoglobulin-like Receptor) with human IgG1 Fc, is safe & tolerable with evidence of immune modulation in subjects with advanced solid tumors

Regular and Young Investigator Award Abstracts2021-11-011 citations

A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.

Journal of Clinical Oncology2021-05-202 citations